Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP1123 | DOI: 10.1530/endoabs.90.EP1123

ECE2023 Eposter Presentations Late Breaking (91 abstracts)

Trends in Prescription of Anti-Diabetic Drugs and Metabolic Control in Type 2 Diabetes: 2015/2016 vs. 2020/2021

Daniela Soares 1 , Isabel Palma 1 , Maria Helena Neto 1 , Mariana Fraga 2 , Joel Pereira 1 , Rosa Guimarães 1 , Maria Helena Cardoso 1 , Ariana Maia 1 & Lia Ferreira 1

1Hospital Geral de Santo António, Endocrinology, Porto, Portugal, 2Hospital Geral de Santo António, Nutrition, Porto, Portugal

Introduction: The development of new pharmacological classes for type 2 diabetes (T2D) treatment with extra-glycaemic benefits has led to the update of the treatment algorithm, presenting new effective alternatives to patients’ insulinization. The present study aims to evaluate the evolution of prescription and its impact in metabolic control of patients enrolled on an educational diabetes program of a tertiary hospital.

Objectives: To evaluate trends on anti-diabetic drugs’ prescription and metabolic outcomes in patients with T2D, comparing the two biennia 2015/2016 and 2020/2021.

Methods: 240 patients were evaluated, 118 in 2015/2016 and 122 in 2020/2021, with no significant differences in general population characterization. In 2020/2021, there was a significant increase in GLP1 agonists (+72,3%, P< 0,001), SGLT2 inhibitors (+66,3%, P< 0,001) and metformin’s (+10,1%, P0,030) prescription, contrary to a decrease in the use of DPP4 inhibitors (-58,9%, P< 0,001), insulin (-12,0%, P0,049) and sulfonylureas (-8,5%, P0,022). Additionally, there was an increase in the use of non-insulin anti-diabetic drugs in triple combination (P< 0,001) and in the de-insulinization rate (+11,9%, P< 0,040). In what concerns metabolic control, we found a higher reduction in weight (-0,4 kg vs. -4,0 kg, P< 0,001) and BMI (-0,16 vs. -1,38, P< 0,001) in 2020/2021, with no significant differences between biennia regarding HbA1c and blood pressure variation.

Conclusions: In 2020/2021, there was an increase in GLP1 agonists, SGLT2 inhibitors and metformin’s use, as well as an increase in de-insulinization rate. In addition, we found a higher reduction in weight and BMI of patients. The differences found demonstrate a growing use of drugs with extra-glycaemic benefits, which reflected in a higher weight loss and allowed the discontinuance of insulin on a significative percentage of patients.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.